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SUMMARY  Sample size calculations are advocated by the Consolidated Standards of Reporting Trials 
(CONSORT) group to justify sample sizes in randomized controlled trials (RCTs). This study aimed to 
analyse the reporting of sample size calculations in trials published as RCTs in orthodontic speciality 
journals. The performance of sample size calculations was assessed and calculations verified where 
possible. Related aspects, including number of authors; parallel, split-mouth, or other design; single- 
or multi-centre study; region of publication; type of data analysis (intention-to-treat or per-protocol 
basis); and number of participants recruited and lost to follow-up, were considered. Of 139 RCTs iden-
tified, complete sample size calculations were reported in 41 studies (29.5 per cent). Parallel designs 
were typically adopted (n = 113; 81 per cent), with 80 per cent (n = 111) involving two arms and 16 per 
cent having three arms. Data analysis was conducted on an intention-to-treat (ITT) basis in a small 
minority of studies (n = 18; 13 per cent). According to the calculations presented, overall, a median 
of 46 participants were required to demonstrate sufficient power to highlight meaningful differences 
(typically at a power of 80 per cent). The median number of participants recruited was 60, with a 
median of 4 participants being lost to follow-up. Our finding indicates good agreement between pro-
jected numbers required and those verified (median discrepancy: 5.3 per cent), although only a minor-
ity of trials (29.5 per cent) could be examined. Although sample size calculations are often reported in 
trials published as RCTs in orthodontic speciality journals, presentation is suboptimal and in need of 
significant improvement.
Introduction
Randomized trials are considered the gold standard for 
assessment of the efficacy and safety of interventions and 
are established in the orthodontic literature. The precedence 
of randomized studies relates to the potential to limit bias 
and confounding effects, which are more likely in obser-
vational studies and non-randomized trials. However, ran-
domized trials are expensive, as well as being time and 
labour intensive; it is imperative, therefore, that studies 
have adequate power to demonstrate a clinically important 
treatment difference if such a difference exists, while being 
able to correctly conclude that no such difference exists as 
indicated (Machin et al., 1997; Schulz and Grimes, 2005). 
Notwithstanding this, unjustifiably large studies carry 
additional expense, risk wasting resources, and may even 
be unethical, as patients can be unnecessarily exposed to 
potentially ineffective therapy.
Studies with small sample sizes tend to be less reliable 
and are more likely to be inconclusive due to inadequate 
statistical power (Freiman et  al., 1978; Altman, 1980; 
Wooding, 1994; Halpern et al., 2002). There is a close rela-
tionship between power and sample size; as sample size 
increases, study power also rises. Recruitment of an appro-
priate sample involves a trade-off between power, feasibil-
ity of the study, ethics, and credibility of the findings. In 
view of  these issues, it is recommended practice to include 
a sample size calculation and justification in both research 
protocols and in reports of randomized trials (Schulz et al., 
2010a, b).
Power calculations should be considered during the 
design stage of clinical trials, being of little value after 
the trial is conducted. At the end of the trial, power may 
be assessed by examining the precision of the estimates 
by observing the width of associated confidence intervals. 
The chief components of the calculation include power 
(typically 80–90 per cent), type I  error or alpha (usually 
0.01 or 0.05), assumptions in the control group (including 
mean response and variance), and expected treatment effect. 
Assumptions pertaining to the control group are usually 
predetermined based on published results or piloting, with 
the expected treatment effect tantamount to a clinically 
meaningful effect. However, incorrect assumptions of 
expected treatment effects and their variance at the design 
stage may lead to insufficient power (Vickers, 2003; Schulz 
and Grimes, 2005). A study designed to detect a clinically 
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important difference with a power of 80 per cent assumes 
an 80 per cent chance of correctly observing a difference 
if such a difference exists. Conversely, it also assumes a 
20 per cent chance of failing to identify a difference (false 
negative) when such a difference does exist. Allowing 
a small likelihood (10–20 per cent) of a false-negative 
outcome (type II error or beta) is unavoidable because to 
guarantee 100 per cent power would necessitate an infinite 
number of participants. Type I  error (or alpha) refers to 
false-positive results and indicates a willingness to accept 
a 5 per cent (P = 0.05) chance of observing a statistically 
significant difference when no such difference exists 
between the treatment groups.
The aim of this study was to assess the quality of report-
ing of sample size calculations in trials published as RCTs 
in eight leading orthodontic journals, to ascertain the num-
ber of participants typically recruited to clinical trials in 
orthodontics, to assess the accuracy of calculations, and 
to identify factors associated with correct performance of 
sample size calculations in orthodontic speciality journals.
Materials and methods
Reports of randomized controlled trials in eight lead-
ing orthodontic journals during a 20-year period up to 
September 2012 were accessed by two authors (DK, PSF). 
Journals included were American Journal of Orthodontics 
and Dentofacial Orthopedics (AJODO), Angle Orthodontist 
(ANGLE), European Journal of Orthodontics (EJO), 
Orthodontics and Craniofacial Research (OCR), Australian 
Orthodontic Journal (AOJ), Journal of Orofacial 
Orthopedics (JO Orthop), Art and Science of Orthodontics 
and Dentofacial Enhancement (formerly World Journal of 
Orthodontics; WJO), and Journal of Orthodontics (JO). 
Relevant articles were hand-searched from the chosen jour-
nals. Two authors (DK, PSF) screened the titles and abstracts 
of potentially relevant articles. A range of randomized tri-
als, including those with two or more arms, parallel group, 
factorial, cluster, and crossover designs were all included. 
Follow-up studies of earlier reports were omitted, however.
The full reports and any supplementary material for all 
selected papers were accessed. A  standard data collection 
form was piloted by 2 authors (DK, PSF) on 10 selected 
papers. Details of the a priori sample size calculation, 
as reported in the Materials and methods section, were 
recorded. In particular, the conduct of a sample size cal-
culation was noted. If conducted, the target sample size, 
number of participants recruited, number of participants 
lost to follow-up, type of analysis (intention-to-treat or per-
protocol basis), and details of the power calculation includ-
ing power, type I  error, assumptions in the control group 
(standard deviation for continuous outcomes, and pro-
portion of events for dichotomous and time-to-event out-
comes), and the expected treatment effect (mean difference 
for continuous outcomes, and difference in the proportion of 
events in the treatment group for dichotomous and time-to-
event outcomes) were recorded. Additional general charac-
teristics recorded included the following:
1. Single- or multi-centre study (binary): Assessed by 
affiliation details and supplementary information on the 
location of the study, as described in the Materials and 
methods section.
2. Number of authors in the publication.
3. Geographical area: The geographic region of the 
first author was recorded and categorized as Europe, 
Americas, or Asia/other.
4. Statistician/methodologist involvement (binary): 
Inferred from author affiliations.
5. Statistical significance (binary): Assessment of signifi-
cance or otherwise.
Sample size calculations for each article reporting sufficient 
data to allow replication were repeated. Where only alpha val-
ues were omitted, an alpha (α) risk of 0.05 with a two-tailed 
test to replicate the calculation was inferred. Sample size 
calculations were replicated with statistical software using 
the sampsi and stpower family of commands (Stata 12.1, 
Statacorp, College Station, Texas, USA). For articles where 
sample size recalculation was feasible, the standardized dif-
ference (per cent) between the actual and estimated sample 
sizes was calculated according to the following formula:
 
Sample size used  Sample size recalculated
Sample size use
−
d
  100×   (1)
Statistical analysis
Descriptive statistics were obtained for the total number 
of articles identified in each journal, location, number of 
researchers, and other characteristics, as well as conduct of 
sample size calculation in individual studies. Chi-square 
test and Fisher’s exact test were used as required to test the 
association of trial characteristics such as journal, conti-
nent of publication, number of authors, design, number of 
research centres and arms, significance of results, and use 
of intention-to-treat (ITT) or other analysis, with sufficient 
reporting or otherwise of sample size calculation details. No 
further statistical analyses were undertaken because of the 
small number of reports with adequate sample size calcu-
lation details. All statistical analyses were conducted with 
statistical software (Stata 12.1, Stata Corp, College Station, 
Texas, USA).
Results
A total of 139 eligible RCTs were identified in eight leading 
orthodontic speciality journals (Table  1, Figure  1). The 
highest percentage of RCTs were published in AJODO 
(n = 61; 44 per cent), with the bulk of the remaining studies 
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published in JO (n = 23; 17 per cent), EJO (n = 21; 15 per 
cent), and ANGLE (n  =  18; 13 per cent). The majority 
of studies were undertaken in a single centre (n = 99; 71 
per cent); most were published by European researchers 
(n = 97; 70 per cent), with parallel designs predominating 
(n = 113; 81 per cent). Eighty per cent (n = 111) of studies 
involved two arms, 16 per cent (n  =  22) had three arms, 
whereas only 4 per cent had more than three groups. 
Statisticians or methodologists were involved in authorship 
in 26 studies (19 per cent), with a slight majority of studies 
reporting statistically significant main outcomes (n = 79; 57 
per cent). Data analysis was conducted on an ITT basis in 
a small minority of studies (n = 18; 13 per cent). In half of 
the analysed RCTs (n = 70), it was unclear whether ITT or 
per-protocol analyses were intended.
Sufficient information to permit verification of the sample 
size calculation was provided in only 41 (29.5 per cent) 
trials (Table 2, Figure 2). A power of 80 per cent was used 
in most of these studies (n = 21; 51 per cent), whereas 90 
per cent power was pre-specified in 15 studies (37 per cent). 
Table 1 Characteristics of the 139 included randomized controlled trials. 
Not included Included Total P value
No. % No. % No. %
Journal
 AJODO 45 46 16 39 61 44 0.02**
 ANGLE 15 15 3 7 18 13 —
 AOJ 2 2 0 0 2 1 —
 EJO 14 14 7 17 21 15 —
 JO 9 9 14 34 23 17 —
 JO Orthop 7 7 0 0 7 5 —
 OCR 4 4 1 2 5 4 —
 WJO 2 2 0 0 2 1 —
Continent
 Europe 59 60 38 93 97 70 <0.001**
 Americas 30 31 0 0 30 22 —
 Asia/other 9 9 3 7 12 9 —
No. of authors
 ≤2 16 16 5 12 21 15 0.80*
 3–4 50 51 21 51 71 51 —
 >5 32 33 15 37 47 34 —
Trial design
 Crossover 7 7 1 2 8 6 0.76**
 Parallel 78 80 35 85 113 81 —
 Split mouth 12 12 5 12 17 12 —
 Split crossover 1 1 0 0 1 1 —
Statistician
 No 85 87 28 68 113 81 0.11*
 Yes 13 13 13 32 26 19 —
Centre
 Single centre 75 77 24 59 99 71 0.09*
 Multi-centre 23 23 17 41 40 29 —
Significance
 No 40 41 20 49 60 43 0.39*
 Yes 58 59 21 51 79 57 —
No. of arms
 2 77 79 34 83 111 80 0.70**
 3 17 17 5 12 22 16 —
 4 1 1 2 5 3 2 —
 5 1 1 0 0 1 1 —
 6 1 1 0 0 1 1 —
 10 1 1 0 0 1 1 —
ITT
 Yes 8 8 10 24 18 13 0.03*
 No 36 37 15 37 51 37 —
 Unclear 54 55 16 39 70 50 —
Total 98 100 41 100 139 100 —
AJODO, American Journal of Orthodontics and Dentofacial Orthopedics; ANGLE, Angle Orthodontist; EJO, European Journal of Orthodontics; OCR, 
Orthodontics and Craniofacial Research; AOJ, Australian Orthodontic Journal; JO Orthop, Journal of Orofacial Orthopedics; Art and Science of 
Orthodontics and Dentofacial Enhancement (formerly World Journal of Orthodontics; WJO); and JO, Journal of Orthodontics. ITT, intention-to-treat 
analysis.
*Chi-square test; **Fisher’s exact test.
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Continuous outcomes predominated in these studies (n = 34; 
83 per cent), with relatively few having either time-to-event 
(n  =  5) or categorical (n  =  2) outcomes (Table  2). Based 
on the complete calculations presented in these 41 RCTs, 
a median of 46 participants were required to demonstrate 
sufficient power; however, a median of 60 participants was 
recruited in each study suggesting over-recruitment of 30.4 
per cent to offset attrition. Overall, the median number of 
participants lost to follow-up was four (Table 3). The cut-off 
point for statistical significance (alpha) was set at 0.05 in all 
of these trials.
Sample size calculations were repeated in the 41 studies 
where it was possible to do so to assess their veracity (Tables 
4 and 5, Figure 3); an overall median discrepancy of 5.3 per 
cent (per cent standardized difference) between presented 
and recalculated sample sizes was found. Median percentage 
difference between the presented and recalculated sample 
sizes ranged from –93.3 to 60.6 per cent. Studies where data 
analysis was undertaken explicitly on an intention-to-treat 
or per-protocol basis had similar calculations, with discrep-
ancies of 6.1 and 8.7 per cent, respectively. More accurate 
sample size calculations were found in studies with power 
of 80 per cent (4.5 per cent) than in those reported to have 
either 85 (45 per cent) or 95 per cent (–30.0 per cent) power.
Discussion
The Consolidated Standards of Reporting Trials 
(CONSORT) group is clear that accurate and transparent 
reporting of the specifics of sample size estimation for 
RCTs is essential (Schulz et  al., 2010a, b). This study is 
the first to analyse execution of sample size calculations in 
orthodontic journals. The overall results were disappoint-
ing, with most studies (70.6 per cent) failing to present 
a complete calculation permitting the calculation to be 
verified. For the small number of trials (29.4 per cent) in 
which sample recalculation was feasible, there was good 
overall agreement between recruited and required samples. 
However, this leaves a lot of room for speculation about the 
remaining 70.6 per cent of the trials. Our results are compa-
rable to a similar research conducted in six general medical 
Figure 2 Bar graph showing frequencies of randomized controlled trials 
(RCTs) justifying sample size calculations by year.
Table 3 Number of participants recruited, required, and 
dropouts.
N Mean Median Minimum Maximum IQR
Recruited 41 70 60 12 187 26
Dropouts 41 9 4 0 50 11
Required 41 57 46 12 176 28
IQR=interquartile range
Figure  1 Flow chart of included studies.RCTs, randomized controlled 
trials.
Table 2 Type of outcome, alpha level, and power level for RCTs 
where sample calculations were shown and could be recalculated.
Included
No. %
Alpha (%)
 5 41 100
Power (%)
 80 21 51
 85 3 7
 90 15 37
 95 2 5
Outcome
 Continuous 34 83
 Categorical 2 5
 Time to event 5 12
Total 41 100
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journals, which demonstrated correct performance of sam-
ple size calculations in 34 per cent of studies, with sufficient 
data present to allow their replication (Charles et al., 2009). 
However, a similar study on surgical publications alluded to 
sample size estimation in just 19 per cent of studies (Ayeni 
et al., 2012). Therefore, it is important that sample size cal-
culations are presented more thoroughly both in dentistry 
generally and in orthodontics. Failing that, if sample size 
calculations continue to be unclear or unreliable, it has been 
suggested that their use should be discontinued (Bacchetti, 
2002).
According to the complete sample size calculations 
obtained, the median number of participants required in 
orthodontic research studies is 46. This number of subjects 
is generally realistic and achievable. It is impossible to 
speculate whether researchers genuinely arrived at these 
figures based on valid assumptions in the control group 
and truly important standardized differences. Clearly, 
however, there is a temptation for researchers to deduce 
a figure that is realistic, of reasonable cost and feasibility, 
yet of sufficient credibility to warrant publication of the 
research. It is known that sample size assumptions can be 
doctored when planning research studies, by retrofitting the 
effect sizes to the available sample; this technique has been 
referred to as ‘sample size samba’ (Schulz and Grimes, 
2005). A  limitation of the present study is that outcomes 
Table 4 Standardized percentage difference for each trial characteristic. 
N Mean Median Minimum Maximum IQR
Journal
 AJODO 16 −6.1 3.5 −93.3 45.0 38.4
 ANGLE 3 −0.5 0.0 −9.1 7.7 16.8
 EJO 7 −9.2 0.0 −66.7 28.9 39.9
 JO 14 19.6 16.1 −41.9 60.6 33.4
 OCR 1 16.7 16.7 16.7 16.7 0.0
 WJO — — — — — —
 AOJ — — — — — —
 JO Orthop — — — — — —
Continent
 Europe 38 5.2 6.5 −93.3 60.6 32.8
 Americas — — — — — —
 Asia/other 3 −23.4 −12.5 −66.7 9.1 75.8
No. of authors
 ≤2 5 −12.6 −9.1 −42.9 23.1 49.4
 3–4 21 −0.3 4.0 −93.3 60.6 41.4
 >5 15 13.2 8.7 −18.2 54.3 23.7
Trial design
 Crossover 1 0.0 0.0 0.0 0.0 0.0
 Parallel 35 0.1 4.5 −93.3 54.3 24.2
 Split mouth 5 25.1 42.1 −66.3 60.6 31.7
 Split crossover — — — — — —
Statistician
 No 28 6.7 8.7 −66.7 60.6 27.9
 Yes 13 −4.6 3.0 −93.3 60.6 27.3
Centre
 Single centre 24 −2.3 4.3 −93.3 60.6 41.7
 Multi-centre 17 10.8 8.7 −41.8 54.3 23.7
Significance
 No 20 −0.3 6.6 −93.3 60.6 53.0
 Yes 21 6.4 5.3 −42.9 60.6 9.1
No. of arms
 2 34 8.2 8.7 −93.3 60.6 28.9
 3 5 −13.1 −12.5 −31.3 0.0 3.4
 4 2 −42.3 −42.3 −42.9 −41.7 1.2
ITT
 Yes 10 3.3 6.1 −42.9 45.0 24.2
 No 15 7.3 8.7 −41.8 54.3 35.2
 Unclear 16 −0.9 4.6 −93.3 60.6 54.3
Total 41 3.1 5.3 −93.3 60.6 35.2
AJODO, American Journal of Orthodontics and Dentofacial Orthopedics; ANGLE, Angle Orthodontist; EJO, European Journal of Orthodontics; OCR, 
Orthodontics and Craniofacial Research; AOJ, Australian Orthodontic Journal; JO Orthop, Journal of Orofacial Orthopedics; Art and Science of 
Orthodontics and Dentofacial Enhancement (formerly World Journal of Orthodontics; WJO); and JO, Journal of Orthodontics. Blank subcategory cells 
indicate that insufficient information was available to allow calculations related to those characteristics to be repeated. ITT, intention-to-treat analysis.
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were based on research reports in isolation. No attempts 
were made to liaise with researchers to ascertain whether 
assumptions had been manipulated to produce realistic 
sample sizes. Consequently, the results presented equate to 
a ‘best-case scenario’, with manipulation of sample sizes 
impossible to identify with the design used. Alterations 
in sample calculations can also be evaluated following 
completion of the study by comparing final publications 
to published protocols. Attempts were made to identify 
protocols for published studies; however, these were rarely 
accessible, as is often the case with orthodontic literature 
(Benson, 2011).
This study confirms that sample size reporting is 
occurring more frequently, with just 4 per cent of reports 
alluding to a calculation in 1980 (Meinert et  al., 1984). 
However, the trial instead demonstrates that calculations 
typically lack the requisite information to permit 
replication. The magnitude of miscalculation shown in 
the complete reviews was small. Although not specifically 
explored in the current study, common reasons for 
discrepancies may relate to incorrect statistical handling 
of nested designs (for example, multiple observations on 
multiple teeth within patients), which may be susceptible 
to clustering effects with outcomes more closely matched 
within clusters than between them (Kerry and Bland, 
1998). Similarity within clusters decreases the amount of 
unique information compared with observations obtained 
without clustering; the required sample size in clustered 
designs increases accordingly (Kerry and Bland, 1998). 
The increase in sample size required in cluster-randomized 
designs can be determined using the design effect, which 
is related to the intra-class  correlation coefficient (ICC) 
according to the following formula: D = 1 + (m − 1) ρ, 
where m is the number of observations per cluster and 
ρ  =  ICC. Higher ICC values require an increase in the 
necessary sample size in a clustered trial to maintain 
similar levels of power. Accurate sample calculations for 
clustered designs requires information relating to either 
the within-cluster correlation (ICC) or the between-
cluster variability (coefficient of variation). However, this 
information is usually lacking.
ITT analysis is increasingly advocated in randomized tri-
als, allowing the benefits of randomization to be preserved 
throughout the trial. The alternative approach is per-protocol 
analysis, where dropouts from clinical studies are ignored in 
the analysis. The latter approach is likely to represent a best-
case scenario and may risk susceptibility to attrition bias 
due to uneven loss to follow-up. Consequently, ITT princi-
ples are advocated for tests of effectiveness of interventions 
in real-world, pragmatic studies. The present study revealed 
that ITT analysis was clearly described and undertaken 
in only a minority of studies (13 per cent). Furthermore, 
although ITT analysis was referred to in a number of other 
studies, closer scrutiny of the flow of participants con-
tradicted this assertion. This finding is in keeping with 
research on medical journals (Gravel et al., 2007) alluding 
to a much greater percentage of studies (62 per cent) using 
ITT, whereas a significant percentage of these violated the 
principles of ITT. Erroneous handling of dropouts in stud-
ies labelled as using ITT analyses ranged from 10 (Hollis 
and Campbell, 1999) to 58 per cent (Kruse et al., 2002). It 
is, therefore, important that data analysis is pre-specified at 
the protocol stage and undertaken and reported accordingly, 
allowing a more informed discussion of the implications of 
research findings.
Table 5 Standardized percentage difference based on alpha 
level, power level, and type of outcome. 
N Mean Median Minimum Maximum IQR
Alpha (%)
 1 — — — — — —
 5 41 3.1 5.3 −93.3 60.6 35.2
Power (%)
 80 21 1.5 4.5 −93.3 60.6 32.2
 85 3 48.1 45.0 45.0 54.3 9.3
 90 15 0.9 7.7 −42.9 33.3 21.2
 95 2 −30.0 −30.0 −41.8 −18.2 23.6
Outcome
 Continuous 34 1.2 4.5 −66.7 54.3 24.26
 Categorical 2 −3.4 −3.4 −12.1 5.3 17.4
 Time to 
event
5 18.7 42.1 −93.3 60.6 36.9
Total 41 3.1 5.3 −93.3 60.6 35.2
Blank subcategory cells indicate that insufficient information was 
available to allow calculations related to those characteristics to be 
repeated.
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Figure 3 Box plots of percentage standardized difference between origi-
nal and recalculated sample size for randomized controlled trials (RCTs) 
in individual orthodontic journals and the overall percentage. Only jour-
nals with trials allowing for sample size recalculation are shown: AJODO, 
American Journal of Orthodontics and Dentofacial Orthopedics; ANGLE, 
Angle Orthodontist; EJO, European Journal of Orthodontics; OCR, 
Orthodontics and Craniofacial Research; and JO, Journal of Orthodontics. 
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The present study has exposed a divide between the 
emphasis placed on sample size calculations by journals, 
ethical review committees, and funding agencies on the 
one hand and existential practice on the other. It appears 
that sample size calculations are reported less often than 
should be the case and, when presented, are sometimes 
inaccurate and often outlined in insufficient detail to permit 
verification. It is, therefore, important that, if the emphasis 
on sample size estimation is to continue, peer reviewers 
and editors be encouraged to scrutinize whether calcula-
tions are presented completely. To facilitate this, publish-
ers may make available electronic software that may also 
permit quick and simple replication of the calculation 
to test its veracity. Unless sound practices are encour-
aged, underpowered trials will continue to be published. 
Although such studies may be combined in meta-analy-
ses, there remains a body of opinion that underpowered 
studies are unethical and may lead to incorrect interpre-
tation of results, particularly when clinical importance is 
confused with statistical significance. Consequently, the 
importance of improving the current methods of sample 
size estimation in published research is clear. Failing that, 
alternative approaches to sample size estimation should be 
considered.
Finally, it should be noted that conclusions from this 
study should be viewed with caution as the proportion of 
RCTs providing enough data for confirmation of sample 
calculations was low. Nevertheless, it should be borne in 
mind that RCTs are often of better methodological qual-
ity compared to non-randomized trials and other studies. 
It is therefore reasonable to speculate that a large body of 
existing evidence may be founded on incorrectly powered 
studies.
Conclusions
Although sample size calculations are typically reported 
in trials published as RCTs in orthodontic speciality jour-
nals, complete presentation is suboptimal. Consequently, 
reporting of sample size estimation is in need of significant 
improvement.
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